The region’s fledgling pharma industry got a shot in the arm with O’Hara-based Thar Pharmaceuticals’ decision to file for an initial public offering worth up to $50 million.

The money will be used to carry the company through phase three testing of its core product, a non-opioidal pain reliever called T-121, which is used to treat severe, persistent pain caused by complex regional pain syndrome.

There is no Food and Drug Administration-approved treatment for the pain, which often follows traumatic injury to the arms or legs, according to the National Institute of Neurological Disorders in Bethesda, Md. More women than men are affected, but its cause is unknown.

Thar plans a clinical trial of T-121, a formulation of zolendronic acid, in the first quarter of 2017 with 150 patients, according to a Securities and Exchange Commission filing. The company, which was formed in 2008, aims to market the first oral medicine for complex regional pain syndrome.

Advertise with us

The company also plans to trade on the Nasdaq exchange under the ticker symbol “Thar.”

“It’s good for Pittsburgh. It’s good for Pennsylvania,” said Pennsylvania Bio president and CEO Christopher Molineaux. Wayne, Pa.-based Pennsylvania Bio is an advocacy group with members in the Pittsburgh area.

Thar’s T-121 is an oral version of a Novartis medicine that can only be administered intravenously, which is sold under the Zometra brand name. Thar is not yet profitable and reported a $3.1 million loss for 2015, according to the SEC filing.

In addition to T-121, Thar is developing a second, non-narcotic pain medication called T-109, which will be used to treat acute pain in the back and after surgery, according to the company.

Other medications in the pipeline include ones for the treatment of cancer, erectile dysfunction, anxiety and migraine headaches.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699